ETHK Labs Subsidiary Unveils AI-Driven Dual-Platform Nipah Virus Detection Solution

IVD Medical Holding Limited ( (HK:1931) ) has issued an update.

ETHK Labs Inc. has announced that its subsidiary Shenzhen ICXIVD Biotechnology has successfully developed a dual-platform solution for Nipah virus detection, addressing an urgent global need for rapid, accurate diagnostics amid a recent Nipah outbreak in India and the broader threat posed by high-fatality zoonotic viruses without existing specific treatments. The new solution, built on ICXIVD’s proprietary AI primer design platform and species-specific nucleic acid database, includes a Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) that is compatible with mainstream PCR equipment, delivers results within an hour, supports flexible throughput configurations and aims to enhance the reliability, speed and scalability of public health emergency responses while advancing the group’s AI healthcare strategy and positioning in molecular diagnostics.

The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.

More about IVD Medical Holding Limited

ETHK Labs Inc., formerly known as IVD Medical Holding Limited, is a Cayman Islands–incorporated high-tech platform focused on intellectual property and life sciences, with a strategic emphasis on pathogen molecular diagnostics and an AI healthcare ecosystem. Through its subsidiary Shenzhen ICXIVD Biotechnology, a molecular diagnostics enterprise integrating R&D, production and technical services, the group aims to provide comprehensive one-stop diagnostic solutions and technological support for the prevention and control of emerging infectious diseases.

Average Trading Volume: 3,166,632

Technical Sentiment Signal: Sell

Current Market Cap: HK$3.03B

Learn more about 1931 stock on TipRanks’ Stock Analysis page.